Shares of Bayer fell more than 10% on Monday after a California judge ruled that Monsanto must pay $289 million for not warning consumers about cancer risks posed by its weedkillers. Bayer acquired Monsanto this year for $63 billion. (Reuters)

The FDA approved a birth-control app to be marketed as a method of contraception for the first time. Natural Cycles uses daily body temperature and menstrual-cycle information to determine when users are fertile. (ABC)

The FDA has signed off on a landmark RNAi-based therapy, which selectively suppresses gene expression, from Alnylam. Marketed as Onpattro, the drug is approved to treat nerve damage. It comes with an average annual list price of $450,000, more than the $300,000 cost-effective ceiling set by ICER. (STAT)

Amicus Therapeutics’ Fabry disease treatment Galafold, which was approved by the FDA on Friday, will have an average list price of $315,000 per year. The drug, the first oral therapy approved by the agency for Fabry disease in more than 15 years, will compete with Sanofi’s Fabrazyme. (Reuters)  

U.S. WorldMeds and Salix Pharmaceuticals are hoping to change the way addiction is treated with Lucemyra, a drug approved by the FDA for the mitigation of opioid-withdrawal symptoms. The company is focusing its outreach on healthcare professionals, as well as Salix’s primary-care salesforce. (MM&M)